Abstract
The present study addressed the hypothesis that the DA transporter ligand, [3H]mazindol, labels multiple sites/states associated with the dopamine (DA) transporter in striatal membranes. Incubations with [3H]mazindol proceeded for 18–24 hr at 4δC in 55.2 mM sodium phosphate buffer, pH 7.4, with a protease inhibitor cocktail. In order to obtain data suitable for quantitative curve fitting, it was necessary to repurify the [3H]mazindol by HPLC before a series of experiments. Under these conditions, we observed greater than 80% specific binding. The method of binding surface analysis was used to characterize the interaction of GBR12935, BTCP, mazindol, and CFT with binding site/sites labeled by [3H]mazindol. A one site model fit the data as well as the two site model: Bmax=16911 fmol/mg protein, Kd of [3H]mazindol=75 nM, Ki of GBR12935 =8.1 nM, Ki of CFT=50 nM and Ki of BTCP=44 nM. The inhibitory mechanism (competitive or noncompetitive) of several drugs (GBR12935, CFT, BTCP, cocaine, cis-flupentixol, nomifensine, WIN35,065-2, bupropion, PCP, and benztropine) was determined. All drugs inhibited [3H]mazindol binding by a competitive mechanism. Although the ligand-selectivity of the [3H]mazindol binding site indicates that it is the uptake inhibitor recognition site of the classic DA transporter, the quantitative differences among the ligand-selectivities of different radioligands for the same site suggest that each radioligand labels different overlapping domains of the DA uptake inhibitor recognition site. It is likely that development of domain-selective drugs may further our under-standing of the DA transporter.
Similar content being viewed by others
References
Wise, R. A. 1981. Brain dopamine and reward. Pages 103–122,in Cooper, S. J., (ed.), Theory in psychopharmacology, Academic Press, London, NY.
Ritz, M. C., Lamb, R. J., Goldberg, S. R., and Kuhar, M. J. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223.
Kuhar, M. J., Ritz, M. C., and Boja, J. W. 1991. The dopamine hypothesis of the reinforcing properties of cocaine. Trends. Neurosci. 14:299–302.
Spealman, R. D., Madras, B. K., and Bergman, J. 1989. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther. 251:142–149.
Bergman, J., Madras, B. K., Johnson, S. E., and Spealman, R. D. 1989. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 251:150–155.
Carroll, F. I., Lewin, A. H., Boja, J. W., and Kuhar, M. J. 1992. Cocaine receptor: biochemical charaterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem. 35:969–981.
Calligaro, D. O., and Eldefrawi, M. E. 1987. Central and peripheral cocaine receptors. J. Pharmacol. Exp. Ther. 243:61–68.
Schoemaker, H., Pimoule, C., Arbilla, S., Scatton, B., Javoy-Agid, F., and Langer, S. Z. 1985. Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease. Naunyn Schmiedeberg' Arch. Pharmacol. 329:227–235.
Madras, B. K., Fahey, M. A., Bergman, J., Canfield, D. R., and Spealman, R. D. 1989. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 251:131–141.
Bonnet, J. J., Protais, P., Chagraoui, A., and Costentin, J. 1986. High-affinity [3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system Eur. J. Pharmacol. 126:211–222.
Berger, P., Janowsky, A. Vocci, F., Skolnik, P., Schweri, M. M., and Paul, S. M. 1985. [3H]GBR 12935: a specific high affinity ligand for labeling the dopamine transport complex. Eur. J. Pharmacol. 107:289–290.
Andersen, P. H. 1987. Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J. Neurochem. 48:1887–1896.
Izenwasser, S., Werling, L. L., Rosenberger, J. G., and Cox, B. M. 1990. Characterization of binding of GBR 12935 (1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropylpiperazine) to membranes and to solubilized membrane extracts from terminal field regions of mesolimbic, mesocortical and nigrostriatal dopamine pathways. Neuropharmacology. 29:1017–1024.
Javitch, J. A., Blaustein, R. O., and Snyder, S. H. 1984. [3H]mazindol binding associated with neuron dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26:35–44.
Reith, M. E. A., Meisler, B. H., Sershen, H., and Lajtha, A. 1986. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 35:1123–1129.
Dubocovich, M. L., and Zahniser, N. R. 1985. Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes. Biochem. Pharmacol. 34:1137–1144.
Vignon, J., Pinet, V., Cerruti, C., Kamenka, J-M., and Chicheportiche, R. 1988. [3H]-[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine [3H]BTCP): a new phencyclidine analog selective for the dopamine uptake complex. Eur. J. Pharmacol. 148:427–436.
Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L., Saha, J. K., and Milius, R. A. 1989. Cocaine receptors labeled by [3H]2β-carbomethoxy-3-β-(4-fluorophenyl)tropane. Mol. Pharmacol. 36:518–524.
Schweri, M. M., Skolnick, P., Rafferty, M. F., Rice, K. C., Janowsky, A. J., and Paul, S. M. 1985. [3H]Threo-(+/−)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45:1062–1070.
Boja, J. W., Patel, A., Carroll, F. I., Rahman, M. A., Philip, A., Lewin, A. H., Kopajtic, T. A., and Kuhar, M. J. 1991. [125I]RTI-55: a potent ligand for dopamine transporters. Eur. J. Pharmacol. 194:133–134.
Kennedy, L. T., and Hanbauer, I. 1983. Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 41:172–178.
Calligaro, D. O., and Eldefrawi, M. E. 1988. High affinity stereospecific binding of [3H]cocaine in striatum and its relationship to the dopamine transporter. Memb. Biochem. 7:87–106.
Reith, M. E. A., and Selmeci, G. 1992. Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn. Schmiedebergs. Arch. Pharmacol. 345:309–318.
Berger, P., Elsworth, J. D., Arroyo, J., and Roth, R. H. 1990. Interaction of [3H]GBR 12935 and GBR 12909 with the dopamine uptake complex in nucleus accumbens. Eur. J. Pharmacol. 177:91–94.
Janowsky, A., Berger, P., Vocci, F., Labarca, R., Skolnick, P., and Paul, S. M. 1986. Characterization of sodium-dependent [3H]GBR-12935 binding in brain: a radioligand for selective labeling of the dopamine transport complex. J. Neurochem. 46:1272–1276.
Sharif, N. A., Nunes, J. L., Michel, A. D., and Whiting, R. L. 1989. Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [3H]GBR12935 binding and [3H]dopamine uptake. Neurochem. Int. 15:325–332.
Hitri, A, Venable, D., Nguyen, H. Q., Casanova, M. F., Kleinman, J. E., and Wyatt, R. J. 1991. Characteristics of [3H]GBR12935 binding in the human and rat frontal cortex. J. Neurochem. 56:1663–1672.
Richfield, E. K. 1991. Quantitative autoradiography of the dopamine uptake complex in rat brain using GBR 12935: binding characteristics. Brain Res. 540:1–13.
Niznik, H. B., Tyndale, R. F., Sallee, F. R., Gonzalez, F. J., Hardwick, J. P., Inaba, T., and Kalow, W. 1990. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylese) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276:424–432.
Boja, J. W., Mitchell, W. M., Patel, A., Kopajtic, T. A., Carroll, F. I., Lewin, A. H., Abraham, P., and Kuhar, M. J. 1992. High affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12:27–36.
Ritz, M. C., Boja, J. W., Grigoriadis, D., Zaczek, R., Carroll, F. I., Lewis, A. H., and Kuhar, M. J. 1990. [3H]WIN 35,065-2:a ligand for cocaine receptors in striatum. J. Neurochem. 55:1556–1562.
Boja, J. W., Rahman, M. A., Philip, A., Lewin, A. H., Carroll, F. I., and Kuhar, M. J. 1991. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter. Mol. Pharmacol. 39:339–345.
Boja, J. W., Markham, L., Patel, A., Uhl, G., and Kuhar, M. J. 1992. Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. Neuroscience/Neuro Report 3:247–248.
Lowry, O. H., Rosenbrough, N. H., Farr, A. L., and Randall, P. J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265–275.
Akunne, H. C., de Costa, B. R., Jacobson, A. E., Rice, K. C., and Rothman, R. B. 1992. [3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochem. Res. 17:1275–1283.
Rothman, R. B. 1983. Analysis of binding surfaces: a methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors. Neuropeptides. 4:41–44.
Rothman, R. B. 1986. Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol and Drug Res. 6:309–325.
Rothman, R. B., Reid, A. A., Mahboubi, A., Kim, C.-H. de Costa, B. R., Jacobson, A. E., and Rice, K. C. 1991. Labeling by [3H]1,3-Di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by ligands. Mol. Pharmacol. 39:222–232.
McGonigle, P., Neve, K. A., and Molinoff, P. B. 1986. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Mol. Pharmacol. 30:329–333.
Rovati, G. E., Rodbard, D., and Munson, P. J. 1990. DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. II Simultaneous analysis of homologous and heterologous competition curves and analysis blocking and of “multiligand” dose-response surfaces. Anal. Biochem. 184:172–183.
Munson, P. J., and Rodbard, D. 1980. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:220–239.
Rothman, R. B., Bykov, V., de Costa, B. R., Jacobson, A. E., Rice, K. C., and Brady, L. S. 1990. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11:311–331.
Reid, A. A., Mattson, M. V., de Costa, B. R., Thurkauf, A., Jacobson, A. E., Monn, J. A., Rice, K. C., and Rothman, R. B. 1990. Specificity of phencyclidine-like drugs and benzomorphan opiates for NMDA-coupled and dopamine uptake carrier associated phencyclidine binding sites in guinea pig brain. Neuropharmacology. 29:811–817.
Rothman, R. B., Reid, A. A., Silverthorn, M., de Costa, B. R., Monn, J. A., Thurkauf, A., Jacobson, A. E., Rice, K. C., and Rogawski, M. A. 1992. Structure-activity studies on the interaction of biogenic amine reuptake inhibitors and potassium channel blockers with MK-801-sensitive (PCP site 1) and-insensitive (PCP site 2) [3H]TCP binding sites in guinea pig brain. Pp. 137–146, in Domino, E. F. and Kamenka, J. M., (eds.), Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Protection, NPP Books, Ann Arbor, MI.
Neve, K. A., McGonigle, P., and Molinoff, P. B. 1986. Quantitativa analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors. J. Pharmacol. Exp. Ther. 238:46–53.
Rothman, R. B., Bykov, V., Mahboubi, A., Long, J. B., Jiang, Q., Porreca, F., de Costa, B. R., Jacobson, A. E., Rice, K. C., and Holaday, J. W. 1991. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex. Synapse 8:86–99.
de Costa, B. R. 1990. Synthesis of high specific activity (3,4-[3H]Cyclohexyl)-N-[1-(2-benzo[b]cyclohexyl]piperid ine ([3H]BTCP): a selective probe for the dopamine reuptake complex. J. Labeled. Comp. Radiopharm. 29:165–173.
Van der Zee, P., Koger, H. S., Gootjes, J., and Hespe, W. 1980. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 15:363–370.
Akunne, H. C., Dersch, H. S., Cadet, J. L., Char, G. U., Partilla, J. S., de Costa, B. R., Rice, K. C., Carroll, F. I., and Rothman, R. B. 1993. Studies of the biogenic amine transporters. III. Demonstration of two binding sites for [3H]GBR12935 and [3H]BTCP in rat caudate membranes. J. Pharmacol. Exp. Ther. (submitted)
Kitayama, S. Shimada, S., Xu, H., Markham, L., Donovan, D. M., and Uhl, G. R. 1992. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. U.S.A. 89:7782–7785.
O'Dowd, B. F., Hantowich, M., Regan, J. W., Leader, W. M., and Caron, M. G. 1988. Site-directed mutagenesis of the cytoplasmic domains of the human beta-2-adrenergic receptor localization of region involved in G protein-receptor coupling. J. Biol. Chem. 263:15985–15992.
Guan, X.-M., Peroutka, S. J., and Kobilka, B. K. 1992. Identification of a single amino acid residue responsible for the binding of a class of β-adrenergic receptor antagonists to 5-hydroxytryptamine1a receptors. Mol. Pharmacol. 41:695–698.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dersch, C.M., Akunne, H.C., Partilla, J.S. et al. Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochem Res 19, 201–208 (1994). https://doi.org/10.1007/BF00966817
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00966817